NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.
24 Jul 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
24 Jul 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
5 Jun 2025 Date | | - Cons. EPS | - EPS |
27 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
24 Jul 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
24 Jul 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
5 Jun 2025 Date | | - Cons. EPS | - EPS |
27 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | - Cons. EPS | - EPS |
Medical - Instruments & Supplies Industry | Healthcare Sector | Ashley Cordova CEO | XDUS Exchange | JE00BYSS4X48 ISIN |
JE Country | 1,488 Employees | - Last Dividend | - Last Split | 2 Oct 2015 IPO Date |
NovoCure Limited is a pioneering oncology company that specializes in the development, manufacture, and commercialization of its innovative tumor treating fields (TTFields) devices for the treatment of various solid tumor cancers. Founded in 2000, NovoCure maintains a strong international presence with operations in the United States, Germany, Japan, Greater China, and other global markets. The company is headquartered in Saint Helier, Jersey, highlighting its global reach and commitment to advancing cancer treatment worldwide. NovoCure's groundbreaking approach focuses on utilizing TTFields technology to target cancer cells, offering a novel treatment option beyond traditional methods. With ongoing clinical trials aimed at expanding the applications of TTFields, NovoCure continues to explore the potential of its technology in treating a wide range of cancers, including brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
Optune Gio is one of NovoCure's flagship TTFields devices, designed specifically for the treatment of glioblastoma, a highly aggressive form of brain cancer. This device represents a significant advancement in the field of oncology, offering a non-invasive treatment option that utilizes low-intensity electric fields to disrupt cancer cell division and growth. By targeting glioblastoma cells while sparing healthy tissue, Optune Gio offers a promising treatment alternative for patients with this challenging condition.
Optune Lua is another innovative TTFields device offered by NovoCure, tailored for the treatment of malignant pleural mesothelioma, a rare cancer linked to asbestos exposure that affects the lining of the lungs. Like Optune Gio, Optune Lua employs TTFields technology to selectively target cancer cells, aiming to inhibit their proliferation and induce cell death. This device provides a critical option for mesothelioma patients, for whom treatment options are often limited and prognosis is typically poor.